Jecure Therapeutics is focused on the discovery of innovative therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis. Jecure’s academic founder is Dr. Ariel Feldstein, Division Chief of Gastroenterology at UCSD School of Medicine and a leading physician-scientist in hepatology. With operations in the biotech hub of San Diego, California, Jecure combines emerging NASH biology from Dr. Feldstein’s lab with an elite discovery team of veteran pharma/biotech scientists. Jecure’s lead program has identified small molecule inhibitors of a novel target and pro-inflammatory driver of NASH. Jecure is backed by top-tier life science investor Versant Ventures.
Company Details
- Founded
- 2016
- Address
- 4757 Nexus Center Drive, San Diego,ca 92121,united States
- Phone
- (888) 888-8888
- in****@****etx.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- jecuretx.com
- Keywords
- San Diego.
- HQ
- San Diego, CA
Jecure Therapeutics Questions
Jecure Therapeutics's helpline number is (888) 888-8888
Jecure Therapeutics's website is jecuretx.com
Jecure Therapeutics's LinkedIn profile is https://www.linkedin.com/company/jecure-therapeutics
Jecure Therapeutics's industry is
Biotechnology Research
Jecure Therapeutics's top competitors are
Elgia Therapeutics, Inc.,
Overwatch Research,
Sorrento Therapeutics, Inc.,
Osmium Partners, Llc,
Xenobiotic Laboratories, Inc., A Wholly Owned Subsidiary Of Wuxi Apptec, Inc.,
Enlaza Therapeutics,
Scientific Pro|search, Inc.,
Vividion Therapeutics, Inc.,
858 Therapeutics,
Stealth.
Jecure Therapeutics's support email address is info@jecuretx.com
Jecure Therapeutics's categories are Biotechnology Research
Jecure Therapeutics's founding year is 2016
